Hydroxychloroquine plus azithromycin early treatment of mild COVID-19 in an outpatient setting: a randomized, double-blinded, placebo-controlled clinical trial evaluating viral clearance
Cristhieni Rodrigues, Rodrigo S Freitas-Santos, José Eduardo Levi, Andreza A Senerchia, Ana Tarina A Lopes, Sergio R Santos, Rinaldo F Siciliano, Lígia C Pierrotti
International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2021.106428
Background: Hydroxychloroquine has shown potential to block viral replication of SARS-CoV-2 in some in vitro studies. This randomised, double-blinded, placebo controlled clinical trial evaluated the efficacy of hydroxychloroquine plus azithromycin (HCQ/AZT) in reducing viral loads in patients with early and mild SARS-CoV-2 infection. Methods: A single-centre randomised placebo-controlled clinical trial was conducted with outpatients with early and mild SARS-CoV-2 infection. Inclusion criteria were: patients aged 18-65 years with symptoms suggestive of COVID-19 for < 5 days, no significant comorbidities, and positive nasopharyngeal/oropharyngeal swab screening tests (POCT-PCR). Randomised patients received either hydroxychloroquine for 7 days plus azithromycin for 5 days or placebo. The primary endpoint was viral clearance within a 9-day period. Secondary endpoints included viral load reduction, clinical evolution, hospitalization rates, chest computed tomography evolution, and adverse effects. Results: From 107 potential trial participants, 84 were enrolled following predetermined criteria. Statistical analyses were performed on an intention-to-treat (N = 84) and per-protocol (PP) basis (N = 70). On the PP analysis, the treatment (N = 36) and placebo (N = 34) groups displayed similar demographic characteristics. At 95% CI, no statistically significant between-group differences were found in viral clearance rates within 9 days following enrolment ( P = 0.26). Conclusions: This randomised, double-blinded, placebo-controlled clinical trial evaluating outpatients with early and mild COVID-19 showed that viral clearance rates within a 9-day period from enrolment did not change with HCQ/AZT treatment compared with placebo, although no major cardiovascular events were observed in participants without comorbidities. Secondary outcomes were also not significantly improved with HCQ/AZT treatment compared with placebo. These findings do not support use of HCQ/AZT in this setting.
DECLARATIONS Funding: This study was funded by Diagnósticos da América S.A. (Dasa), Ímpar Serviços Hospitalares S.A., and DNA Capital Foundation. Competing Interests: All authors report no conflicts of interest relevant to this article. Ethical Approval: The present study was designed as a prospective, double blinded, placebo-controlled, randomised clinical trial, in accordance with The Consolidated Standards of Reporting Trials (CONSORT) Statement, approved by the local ethics and research committee, registered at REBEC (30413020.8.0 0 0 0.0 0 08),
Supplementary materials Supplementary material associated with this article can be found, in the online version, at doi: 10.1016/j.ijantimicag.2021. 106428 .
References
Boulware, Pullen, Bangdiwala, Pastick, Lofgren et al., A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19, N Eng J Med
Cavalcanti, Zampieri, Rosa, Azevedo, Veiga et al., Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19, N Eng J Med
Corman, Landt, Kaiser, Molenkamp, Meijer et al., Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR, Eurosurveillance
Damle, Vourvahis, Wang, Leaney, Corrigan, Clinical pharmacology perspectives on the antiviral activity of azithromycin and use in COVID-19, Clin Pharmacol Therapeut
Dong, Hu, Gao, Discovering drugs to treat coronavirus disease 2019 (COVID-19), Drug Discov Ther
Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents
Geleris, Sun, Platt, Zucker, Baldwin et al., Observational study of hydroxychloroquine in hospitalized patients with Covid-19, N Eng J Med
Ghazy, Almaghraby, Shaaban, Kamal, Beshir et al., A systematic review and meta-analysis on chloroquine and hydroxychloroquine as monotherapy or combined with azithromycin in COVID-19 treatment, Sci Reports
Harris, Taylor, Minor, Elliott, Fernandez et al., The RED-Cap consortium: Building an international community of software platform partners, J Biomed Informatics
Lachin, Foulkes, Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification, Biometrics
Liu, Cao, Xu, Wang, Zhang et al., Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro, Cell Disc
Mahevas, Tran, Roumier, Chabrol, Paule et al., No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial, Medrxiv
Million, Lagier, Gautret, Colson, Fournier et al., Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France, Travel Med Infect Dis
Mitjà, Corbacho-Monné, Ubals, Tebe, Penafiel et al., Hydroxychloroquine for early treatment of adults with mild Covid-19: a randomized-controlled trial, Clin Infect Dis
Nicol, Joshi, Rizk, Sabato, Savic et al., Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 Infection, Clin Pharmacol Therapeut
Organization, WHO coronavirus disease (COVID-19) dashboard
Perinel, Launay, Botelho-Nevers, Diconne, Louf-Durier et al., Towards optimization of hydroxychloroquine dosing in intensive care unit COVID-19 patients, Clin Infect Dis
Principi, Esposito, Chloroquine or hydroxychloroquine for prophylaxis of COVID-19, Lancet Infect Dis
Rosenberg, Dufort, Udo, Wilberschied, Kumar et al., Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State, JAMA
Tang, Cao, Han, Wang, Chen et al., Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial, BMJ
Team, R: A language and environment for statistical computing
Touret, Gilles, Barral, Nougairéde, Van Helden et al., In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication, Sci Reports
Trial, No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res
Yao, Ye, Zhang, Cui, Huang et al., In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Clin Infect Dis
Zimmermann, Ziesenitz, Curtis, Ritz, The immunomodulatory effects of macrolides-a systematic review of the underlying mechanisms, Front Immunol
{ 'indexed': {'date-parts': [[2024, 1, 22]], 'date-time': '2024-01-22T11:39:47Z', 'timestamp': 1705923587338},
'reference-count': 27,
'publisher': 'Elsevier BV',
'issue': '5',
'license': [ { 'start': { 'date-parts': [[2021, 11, 1]],
'date-time': '2021-11-01T00:00:00Z',
'timestamp': 1635724800000},
'content-version': 'tdm',
'delay-in-days': 0,
'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}],
'content-domain': { 'domain': [ 'clinicalkey.jp', 'clinicalkey.com', 'clinicalkey.es', 'clinicalkey.com.au',
'clinicalkey.fr', 'elsevier.com', 'sciencedirect.com'],
'crossmark-restriction': True},
'published-print': {'date-parts': [[2021, 11]]},
'DOI': '10.1016/j.ijantimicag.2021.106428',
'type': 'journal-article',
'created': {'date-parts': [[2021, 8, 25]], 'date-time': '2021-08-25T15:20:06Z', 'timestamp': 1629904806000},
'page': '106428',
'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy',
'source': 'Crossref',
'is-referenced-by-count': 10,
'title': 'Hydroxychloroquine plus azithromycin early treatment of mild COVID-19 in an outpatient setting: '
'a randomized, double-blinded, placebo-controlled clinical trial evaluating viral clearance',
'prefix': '10.1016',
'volume': '58',
'author': [ { 'ORCID': 'http://orcid.org/0000-0002-5002-0953',
'authenticated-orcid': False,
'given': 'Cristhieni',
'family': 'Rodrigues',
'sequence': 'first',
'affiliation': []},
{ 'ORCID': 'http://orcid.org/0000-0002-4604-4549',
'authenticated-orcid': False,
'given': 'Rodrigo S.',
'family': 'Freitas-Santos',
'sequence': 'additional',
'affiliation': []},
{'given': 'José Eduardo', 'family': 'Levi', 'sequence': 'additional', 'affiliation': []},
{'given': 'Andreza A.', 'family': 'Senerchia', 'sequence': 'additional', 'affiliation': []},
{'given': 'Ana Tarina A.', 'family': 'Lopes', 'sequence': 'additional', 'affiliation': []},
{'given': 'Sergio R.', 'family': 'Santos', 'sequence': 'additional', 'affiliation': []},
{'given': 'Rinaldo F.', 'family': 'Siciliano', 'sequence': 'additional', 'affiliation': []},
{'given': 'Lígia C.', 'family': 'Pierrotti', 'sequence': 'additional', 'affiliation': []}],
'member': '78',
'reference': [ { 'key': '10.1016/j.ijantimicag.2021.106428_bib0001',
'unstructured': 'Organization GWH. WHO coronavirus disease (COVID-19) dashboard. '
'Available at: https://covid19.who.int/[accessed 07 June 2021 ].'},
{ 'issue': '1',
'key': '10.1016/j.ijantimicag.2021.106428_bib0002',
'doi-asserted-by': 'crossref',
'first-page': '58',
'DOI': '10.5582/ddt.2020.01012',
'article-title': 'Discovering drugs to treat coronavirus disease 2019 (COVID-19)',
'volume': '14',
'author': 'Dong',
'year': '2020',
'journal-title': 'Drug Discov Ther'},
{ 'issue': '1',
'key': '10.1016/j.ijantimicag.2021.106428_bib0003',
'doi-asserted-by': 'crossref',
'first-page': '1',
'DOI': '10.1038/s41421-019-0132-8',
'article-title': 'Hydroxychloroquine, a less toxic derivative of chloroquine, is '
'effective in inhibiting SARS-CoV-2 infection in vitro',
'volume': '6',
'author': 'Liu',
'year': '2020',
'journal-title': 'Cell Disc'},
{ 'issue': '1',
'key': '10.1016/j.ijantimicag.2021.106428_bib0004',
'doi-asserted-by': 'crossref',
'DOI': '10.1016/j.ijantimicag.2020.105949',
'article-title': 'Hydroxychloroquine and azithromycin as a treatment of COVID-19: results '
'of an open-label non-randomized clinical trial',
'volume': '56',
'author': 'Gautret',
'year': '2020',
'journal-title': 'Int J Antimicrob Agents'},
{ 'issue': '3',
'key': '10.1016/j.ijantimicag.2021.106428_bib0005',
'doi-asserted-by': 'crossref',
'first-page': '269',
'DOI': '10.1038/s41422-020-0282-0',
'article-title': 'Remdesivir and chloroquine effectively inhibit the recently emerged '
'novel coronavirus (2019-nCoV) in vitro',
'volume': '30',
'author': 'Wang',
'year': '2020',
'journal-title': 'Cell Res'},
{ 'issue': '1',
'key': '10.1016/j.ijantimicag.2021.106428_bib0006',
'first-page': '1',
'article-title': 'In vitro screening of a FDA approved chemical library reveals potential '
'inhibitors of SARS-CoV-2 replication',
'volume': '10',
'author': 'Touret',
'year': '2020',
'journal-title': 'Sci Reports'},
{ 'issue': '2',
'key': '10.1016/j.ijantimicag.2021.106428_bib0007',
'doi-asserted-by': 'crossref',
'first-page': '201',
'DOI': '10.1002/cpt.1857',
'article-title': 'Clinical pharmacology perspectives on the antiviral activity of '
'azithromycin and use in COVID-19',
'volume': '108',
'author': 'Damle',
'year': '2020',
'journal-title': 'Clin Pharmacol Therapeut'},
{ 'key': '10.1016/j.ijantimicag.2021.106428_bib0008',
'doi-asserted-by': 'crossref',
'first-page': '302',
'DOI': '10.3389/fimmu.2018.00302',
'article-title': 'The immunomodulatory effects of macrolides—a systematic review of the '
'underlying mechanisms',
'volume': '9',
'author': 'Zimmermann',
'year': '2018',
'journal-title': 'Front Immunol'},
{ 'key': '10.1016/j.ijantimicag.2021.106428_bib0009',
'doi-asserted-by': 'crossref',
'first-page': 'ciaa1009',
'DOI': '10.1093/cid/ciaa1009',
'article-title': 'Hydroxychloroquine for early treatment of adults with mild Covid-19: a '
'randomized-controlled trial',
'volume': '2000',
'author': 'Mitjà',
'year': '2020',
'journal-title': 'Clin Infect Dis'},
{ 'key': '10.1016/j.ijantimicag.2021.106428_bib0010',
'first-page': '369',
'article-title': 'Hydroxychloroquine in patients with mainly mild to moderate coronavirus '
'disease 2019: open label, randomised controlled trial',
'author': 'Tang',
'year': '2020',
'journal-title': 'BMJ'},
{ 'issue': '25',
'key': '10.1016/j.ijantimicag.2021.106428_bib0011',
'doi-asserted-by': 'crossref',
'first-page': '2411',
'DOI': '10.1056/NEJMoa2012410',
'article-title': 'Observational study of hydroxychloroquine in hospitalized patients with '
'Covid-19',
'volume': '382',
'author': 'Geleris',
'year': '2020',
'journal-title': 'N Eng J Med'},
{ 'issue': '24',
'key': '10.1016/j.ijantimicag.2021.106428_bib0012',
'doi-asserted-by': 'crossref',
'first-page': '2493',
'DOI': '10.1001/jama.2020.8630',
'article-title': 'Association of treatment with hydroxychloroquine or azithromycin with '
'in-hospital mortality in patients with COVID-19 in New York State',
'volume': '323',
'author': 'Rosenberg',
'year': '2020',
'journal-title': 'JAMA'},
{ 'issue': '21',
'key': '10.1016/j.ijantimicag.2021.106428_bib0013',
'doi-asserted-by': 'crossref',
'first-page': '2041',
'DOI': '10.1056/NEJMoa2019014',
'article-title': 'Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate '
'Covid-19',
'volume': '383',
'author': 'Cavalcanti',
'year': '2020',
'journal-title': 'N Eng J Med'},
{ 'key': '10.1016/j.ijantimicag.2021.106428_bib0014',
'article-title': 'No evidence of clinical efficacy of hydroxychloroquine in patients '
'hospitalized for COVID-19 infection with oxygen requirement: results of '
'a study using routinely collected data to emulate a target trial',
'author': 'Mahevas',
'year': '2020',
'journal-title': 'Medrxiv'},
{ 'key': '10.1016/j.ijantimicag.2021.106428_bib0015',
'doi-asserted-by': 'crossref',
'DOI': '10.1016/j.tmaid.2020.101738',
'article-title': 'Early treatment of COVID-19 patients with hydroxychloroquine and '
'azithromycin: A retrospective analysis of 1061 cases in Marseille, '
'France',
'volume': '35',
'author': 'Million',
'year': '2020',
'journal-title': 'Travel Med Infect Dis'},
{ 'key': '10.1016/j.ijantimicag.2021.106428_bib0016',
'unstructured': 'Trial R. No clinical benefit from use of hydroxychloroquine in '
'hospitalised patients with COVID-19. Press release from the chief '
'investigators of the Randomised Evaluation of COVid-19 thERapY '
'(RECOVERY) Trial '
'(https://www.recoverytrial.net/news/statement-from-the-chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on-hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in-hospitalised-patients-with-covid-19). '
'2020 [last accessed 07 Jun 2021].'},
{ 'issue': '1',
'key': '10.1016/j.ijantimicag.2021.106428_bib0017',
'first-page': '1',
'article-title': 'A systematic review and meta-analysis on chloroquine and '
'hydroxychloroquine as monotherapy or combined with azithromycin in '
'COVID-19 treatment',
'volume': '10',
'author': 'Ghazy',
'year': '2020',
'journal-title': 'Sci Reports'},
{ 'key': '10.1016/j.ijantimicag.2021.106428_bib0018',
'unstructured': 'ClinicalTrials.gov. ClinicalTrials.gov “Basic Results” Data Element '
'Definitions. 2013. Available at: '
'http://prsinfo.clinicaltrials.gov/results_definitions.html#AdverseEventsDefinition). '
'[accessed 07 June 2021].'},
{ 'key': '10.1016/j.ijantimicag.2021.106428_bib0019',
'doi-asserted-by': 'crossref',
'DOI': '10.1016/j.jbi.2019.103208',
'article-title': 'The REDCap consortium: Building an international community of software '
'platform partners',
'volume': '95',
'author': 'Harris',
'year': '2019',
'journal-title': 'J Biomed Informatics'},
{ 'key': '10.1016/j.ijantimicag.2021.106428_bib0020',
'series-title': 'R: A language and environment for statistical computing',
'author': 'Team',
'year': '2013'},
{ 'key': '10.1016/j.ijantimicag.2021.106428_bib0021',
'doi-asserted-by': 'crossref',
'first-page': '507',
'DOI': '10.2307/2531201',
'article-title': 'Evaluation of sample size and power for analyses of survival with '
'allowance for nonuniform patient entry, losses to follow-up, '
'noncompliance, and stratification',
'author': 'Lachin',
'year': '1986',
'journal-title': 'Biometrics'},
{ 'issue': '3',
'key': '10.1016/j.ijantimicag.2021.106428_bib0022',
'doi-asserted-by': 'crossref',
'DOI': '10.2807/1560-7917.ES.2020.25.3.2000045',
'article-title': 'Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR',
'volume': '25',
'author': 'Corman',
'year': '2020',
'journal-title': 'Eurosurveillance'},
{ 'issue': '6',
'key': '10.1016/j.ijantimicag.2021.106428_bib0023',
'doi-asserted-by': 'crossref',
'first-page': '1135',
'DOI': '10.1002/cpt.1993',
'article-title': 'Pharmacokinetics and Pharmacological Properties of Chloroquine and '
'Hydroxychloroquine in the Context of COVID-19 Infection',
'volume': '108',
'author': 'Nicol',
'year': '2020',
'journal-title': 'Clin Pharmacol Therapeut'},
{ 'issue': '15',
'key': '10.1016/j.ijantimicag.2021.106428_bib0024',
'doi-asserted-by': 'crossref',
'first-page': '732',
'DOI': '10.1093/cid/ciaa237',
'article-title': 'In vitro antiviral activity and projection of optimized dosing design '
'of hydroxychloroquine for the treatment of severe acute respiratory '
'syndrome coronavirus 2 (SARS-CoV-2)',
'volume': '71',
'author': 'Yao',
'year': '2020',
'journal-title': 'Clin Infect Dis'},
{ 'issue': '16',
'key': '10.1016/j.ijantimicag.2021.106428_bib0025',
'doi-asserted-by': 'crossref',
'first-page': '2227',
'DOI': '10.1093/cid/ciaa394',
'article-title': 'Towards optimization of hydroxychloroquine dosing in intensive care '
'unit COVID-19 patients',
'volume': '71',
'author': 'Perinel',
'year': '2020',
'journal-title': 'Clin Infect Dis'},
{ 'issue': '6',
'key': '10.1016/j.ijantimicag.2021.106428_bib0026',
'doi-asserted-by': 'crossref',
'first-page': '517',
'DOI': '10.1056/NEJMoa2016638',
'article-title': 'A randomized trial of hydroxychloroquine as postexposure prophylaxis '
'for Covid-19',
'volume': '383',
'author': 'Boulware',
'year': '2020',
'journal-title': 'N Eng J Med'},
{ 'issue': '10',
'key': '10.1016/j.ijantimicag.2021.106428_bib0027',
'doi-asserted-by': 'crossref',
'first-page': '1118',
'DOI': '10.1016/S1473-3099(20)30296-6',
'article-title': 'Chloroquine or hydroxychloroquine for prophylaxis of COVID-19',
'volume': '20',
'author': 'Principi',
'year': '2020',
'journal-title': 'Lancet Infect Dis'}],
'container-title': 'International Journal of Antimicrobial Agents',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S0924857921002065?httpAccept=text/xml',
'content-type': 'text/xml',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'https://api.elsevier.com/content/article/PII:S0924857921002065?httpAccept=text/plain',
'content-type': 'text/plain',
'content-version': 'vor',
'intended-application': 'text-mining'}],
'deposited': { 'date-parts': [[2021, 10, 25]],
'date-time': '2021-10-25T16:10:32Z',
'timestamp': 1635178232000},
'score': 1,
'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S0924857921002065'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2021, 11]]},
'references-count': 27,
'journal-issue': {'issue': '5', 'published-print': {'date-parts': [[2021, 11]]}},
'alternative-id': ['S0924857921002065'],
'URL': 'http://dx.doi.org/10.1016/j.ijantimicag.2021.106428',
'relation': {},
'ISSN': ['0924-8579'],
'subject': ['Pharmacology (medical)', 'Infectious Diseases', 'Microbiology (medical)', 'General Medicine'],
'container-title-short': 'International Journal of Antimicrobial Agents',
'published': {'date-parts': [[2021, 11]]},
'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'},
{ 'value': 'Hydroxychloroquine plus azithromycin early treatment of mild COVID-19 in an '
'outpatient setting: a randomized, double-blinded, placebo-controlled clinical '
'trial evaluating viral clearance',
'name': 'articletitle',
'label': 'Article Title'},
{ 'value': 'International Journal of Antimicrobial Agents',
'name': 'journaltitle',
'label': 'Journal Title'},
{ 'value': 'https://doi.org/10.1016/j.ijantimicag.2021.106428',
'name': 'articlelink',
'label': 'CrossRef DOI link to publisher maintained version'},
{'value': 'article', 'name': 'content_type', 'label': 'Content Type'},
{ 'value': '© 2021 Elsevier Ltd and International Society of Antimicrobial Chemotherapy. '
'All rights reserved.',
'name': 'copyright',
'label': 'Copyright'}],
'article-number': '106428'}
